# A randomised prospective study to investigate the efficacy of corneal collagen cross linkage with riboflavin (vitamin B2) and ultraviolet A light (UVA) (370nm) to halt the progression of keratoconus

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
28/09/2007		☐ Protocol		
Registration date 28/09/2007	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
12/12/2013	Eye Diseases			

## Plain English summary of protocol

Not provided at time of registration

## Contact information

## Type(s)

Scientific

#### Contact name

Mr David O'Brart

#### Contact details

Opthalmology F00, South Wing (Block 7) St. Thomas' Hospital Lambeth Palace Road London United Kingdom SE1 7RH +44 (0)207 1887 188 davidobrart@aol.com

## Additional identifiers

Protocol serial number N0013180304

## Study information

#### Scientific Title

#### **Study objectives**

The aim is to determine whether the progression of keratoconus can be halted by strengthening the cornea by cross-linkage of its collagen using ultraviolet A (UVA) light and riboflavin (vitamin B) as a photosensitizer.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomized, bilateral-controlled, prospective clinical investigation

#### Primary study design

Interventional

#### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Keratoconus

#### **Interventions**

Randomized, bilateral-controlled, prospective clinical investigation (one eye acts as control while opposite acts as study) whereby riboflavin eye drops are applied and ultraviolet A light is shone into corneal surface. Study group undergoes full ophthalmic examination of both eyes, a full refraction test, corneal topography, keratometry, corneal pachymetry and applanation tonometry, at 1 day, week, month then month 3, 6, 12 & 18.

### Intervention Type

Supplement

#### Phase

**Not Specified** 

## Drug/device/biological/vaccine name(s)

riboflavin (vitamin B2)

#### Primary outcome(s)

To determine whether Riboflavin/ UVA corneal cross-linkage can prevent the progression of keratoconus. The non-treated eye will act as a control.

### Key secondary outcome(s))

To determine whether Riboflavin/UVA corneal cross-linkage can reverse some of the bowing of the cornea caused by keratoconus. To determine whether non-treated eyes have progression of keratoconus compared to those eyes which underwent cross-linkage treatment.

#### Completion date

04/12/2007

## **Eligibility**

#### Key inclusion criteria

36 patients with moderate bilateral keratoconus recruited from the corneal and contact lens clinics at Guy's and St. Thomas' NHS Foundation Trust. Inclusion criteria:

- 1. Age 18 to 70
- 2. Must fully understand the investigative nature of the study
- 3. Moderate to advanced bilateral keratoconus
- 4. No known allergies to pre- and post-operative medications Willingness to attend for follow-up examinations

#### Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

Adult

### Lower age limit

18 years

#### Sex

**Not Specified** 

#### Key exclusion criteria

- 1. Age below 18
- 2. Other pre-existing ophthalmic pathology
- 3. Previous ophthalmic surgery
- 4. Unilateral keratoconus
- 5. Severe keratoconus in which the cornea is so distorted that accurate refractive and corneal measurements cannot be obtained (in these eyes data confirming stability or progression is not possible)

#### Date of first enrolment

05/06/2006

#### Date of final enrolment

04/12/2007

## Locations

#### Countries of recruitment

**United Kingdom** 

England

Study participating centre Opthalmology

London United Kingdom SE1 7RH

## Sponsor information

### Organisation

Record Provided by the NHSTCT Register - 2007 Update - Department of Health

## Funder(s)

### Funder type

Government

#### **Funder Name**

Guy's and St. Thomas' NHS Foundation Trust

#### **Funder Name**

Own account

#### **Funder Name**

NHS R&D Support Funding

## **Results and Publications**

Individual participant data (IPD) sharing plan

IPD sharing plan summary

## Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2011		Yes	No